The pleiotropic association between IL-10 levels and CVD prognosis: Evidence from a meta-analysis
The pleiotropic association between IL-10 levels and CVD prognosis: Evidence from a meta-analysis
复制标题
IL-10 水平与 CVD 预后之间的多效性关联：来自荟萃分析的证据
DOI：
10.1016/j.cyto.2019.02.017
复制
发表时间：
2019
期刊：
影响因子：
3.8
通讯作者：
Lu Lu
中科院分区：
文献类型：
--
作者：
Ni Shi Hao;Sun Shu ning;Huang Zeng Yan;Huang Yu Sheng;Li Huan;Wang Jia Jia;Xian Shao Xiang;Yang Zhong Qi;Wang Ling Jun;Lu Lu
我们研究了IL-10水平与心血管疾病（CVD）预后之间的确切关系，并探讨了IL-10在不同心脏病理中的多效性作用。我们对调查IL-10水平的横断面和纵向研究进行了荟萃分析。meta回归分析用于确定差异的原因。为了评估发表偏倚，我们构建了漏斗图，并进行了Egger检验。来自GSE58015数据集的数据用于研究特定条件下IL-10的水平。由于用于比较心血管疾病患者和健康人之间IL-10水平的数据存在很大的异质性，我们无法确定健康对照组与缺血性或非缺血性病变患者之间的差异（p > 0.05）。分析il - 10水平和心血管疾病预后之间的关系表明,更高的il - 10水平与患者的不良预后显著相关非缺血型病态(HR = 1.10,95% CI = 1.00 - -1.20,p = 0.043)与患者的预后相关但不同缺血性病理基于采样时间点(之前经皮冠状动脉介入(PCI):人力资源 = 4.90,95% CI = 1.24 - -19.30,p < 0.001;PCI后:人力资源 = 0.57,95% CI = 0.43 - -0.75,p = 0.023)。meta回归分析显示，IL-10水平的合并HR与IL-10/IL-6比值呈正相关（β = 0.644,p = 0.024）。漏斗图和Egger’s检验显示我们的meta分析没有统计学上显著的偏差（p > 0.1）。此外，我们的数据挖掘分析支持了我们的发现。我们的分析表明，IL-10水平可能与CVD预后多效性相关，这可能基于病理类型、疾病分期和其他促炎因子（如IL-6）的水平。
We examined the precise association between IL-10 levels and cardiovascular disease (CVD) prognosis and explored the pleiotropic role of IL-10 in different cardiac pathologies. We performed a meta-analysis of cross-sectional and longitudinal studies investigating IL-10 levels. Meta-regression analyses were used to determine the cause of the discrepancies. To assess publication bias, funnel plots were constructed, and Egger’s tests were performed. Data from the GSE58015 dataset were used to investigate the levels of IL-10 under certain conditions. Because of substantial heterogeneity in the data used to compare the IL-10 levels between patients with CVD and healthy people, we could not determine the differences between the healthy controls and patients with ischemic or nonischemic pathologies (p > 0.05). The analysis of the association between IL-10 levels and CVD prognosis indicated that higher IL-10 levels were significantly associated with a poor prognosis in patients with nonischemic pathologies (HR = 1.10, 95% CI = 1.00–1.20, p = 0.043) but differentially associated with the prognosis of patients with ischemic pathologies based on the sampling time point (before percutaneous coronary intervention (PCI): HR = 4.90, 95% CI = 1.24–19.30, p < 0.001; after PCI: HR = 0.57, 95% CI = 0.43–0.75, p = 0.023). Themeta-regression analysis showed that the pooled HR of the IL-10 levels was positively correlated with the IL-10/IL-6 ratio (β = 0.644, p = 0.024). The funnel plots and Egger’s tests revealed no statistically significant bias in our meta-analysis (p > 0.1). Furthermore, our data mining analysis supported our findings. Our analysis showed that IL-10 levels may be pleiotropically associated with the CVD prognosis possibly based on the type of pathology, disease stage and levels of other proinflammatory factors, such as IL-6.